Symposia: Aggressive Lymphomas: Prospective Therapeutic Trials
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Bispecific Antibody Therapy, Non-Biological therapies, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Checkpoint Inhibitor, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Technology and Procedures, molecular testing
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Bispecific Antibody Therapy, Non-Biological therapies, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Checkpoint Inhibitor, Diseases, Therapies, therapy sequence, Lymphoid Malignancies, Technology and Procedures, molecular testing
Monday, December 11, 2023: 2:45 PM-4:15 PM
Seaport Ballroom ABCD
(Manchester Grand Hyatt San Diego)
Moderators:
Hua-Jay J Cherng, MD, Columbia University
and
Annalisa Chiappella, MD, Fondazione IRCCS Istituto Nazionale dei Tumori
Disclosures:
Chiappella: Gilead-Sciences: Other: lecture fee/educational activities, advisory board; Novartis: Other: lecture fee/educational activities; Celgene-BMS: Other: lecture fee/educational activities, advisory board; SecuraBIO: Other: advisory board; Incyte: Other: lecture fee/educational activities; AstraZeneca: Other: lecture fee/educational activities; Jannsen-Cilag: Other: lecture fee/educational activities, advisory board; Roche: Other: lecture fee/educational activities, advisory board; Ideogen: Other: advisory board; Takeda: Other: lecture fee/educational activities, advisory board.
2:45 PM
3:00 PM
3:15 PM
3:30 PM
3:45 PM
4:00 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH